Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance

References

• Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med. 2011;62:249–264.
   PubMed Web of Science ®Google Scholar
• Torimoto Y, Shindo M, Ikuta K, et al. Current therapeutic strategies for multiple myeloma. Int J Clin Oncol. 2015;20:423–430.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617.
   PubMed Web of Science ®Google Scholar
• Kapoor P, Ramakrishnan V, Rajkumar SV. Bortezomib combination therapy in multiple myeloma. Semin Hematol. 2012;49:228–242.
   PubMed Web of Science ®Google Scholar
• Kouroukis TC, Baldassarre FG, Haynes AE, et al. Bortezomib in multiple myeloma: systematic review and clinical considerations. Curr Oncol. 2014;21:e573–e603.
   PubMed Web of Science ®Google Scholar
• Cao B, Li J, Mao X. Dissecting bortezomib: development, application, adverse effects and future direction. Curr Pharm Des. 2013;19:3190–3200.
   PubMed Web of Science ®Google Scholar
• Chen D, Frezza M, Schmitt S, et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11:239–253.
   PubMed Web of Science ®Google Scholar
• Driscoll JJ, Chowdhury RD. Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications. Cancer Lett. 2012;325:147–154.
   PubMed Web of Science ®Google Scholar
• Mimura N, Hideshima T, Anderson KC. Novel therapeutic strategies for multiple myeloma. Exp Hematol. 2015;43:732–741.
   PubMed Web of Science ®Google Scholar
• Lin L, Gaut D, Hu K, et al. Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474). Int J Oncol. 2014;44:557–562.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Hideshima T, Fulciniti M, et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010;116:1460–1468.
   PubMed Web of Science ®Google Scholar
• Meng H, Yang C, Jin J, et al. Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Leuk Lymphoma. 2008;49:1954–1962.
   PubMed Web of Science ®Google Scholar
• Azab F, Vali S, Abraham J, et al. PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance. Br J Haematol. 2014;165:89–101.
   PubMed Web of Science ®Google Scholar
• Sahin I, Azab F, Mishima Y, et al. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. Am J Hematol. 2014;89:1030–1036.
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang M, Cao B, et al. Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma. Curr Med Chem. 2014;21:3173–3187.
   PubMed Web of Science ®Google Scholar
• Glauer J, Pletz N, Schon M, et al. A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo. Blood Cancer J. 2013;3:e141.
   PubMed Web of Science ®Google Scholar
• Martelli AM, Evangelisti C, Chappell W, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia. 2011;25:1064–1079.
   PubMed Web of Science ®Google Scholar
• Neri A, Marmiroli S, Tassone P, et al. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008;49:1374–1383.
   PubMed Web of Science ®Google Scholar
• Burger MT, Pecchi S, Wagman A, et al. Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer. ACS Med Chem Lett. 2011;2:774–779.
   PubMed Web of Science ®Google Scholar
• Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11:317–328.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yang J, Qian J, et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med. 2012;90:695–706.
   PubMed Web of Science ®Google Scholar
• Martin SK, Gan ZY, Fitter S, et al. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leuk Res. 2015;39:380–387.
   PubMed Web of Science ®Google Scholar
• Yip PY. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res. 2015;4:165–176.
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Ma W, Wang ZQ, et al. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011;286:11009–11020.
   PubMed Web of Science ®Google Scholar
• Chim CS, Pang R, Fung TK, et al. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 2007;21:2527–2536.
   PubMed Web of Science ®Google Scholar
• Chong KY, Hsu CJ, Hung TH, et al. Wnt pathway activation and ABCB1 expression account for attenuation of proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells. Cancer Biol Ther. 2015;16:149–159.
   PubMed Web of Science ®Google Scholar
• Kim Y, Reifenberger G, Lu D, et al. Influencing the Wnt signaling pathway in multiple myeloma. Anticancer Res. 2011;31:725–730.
   PubMed Web of Science ®Google Scholar
• Rzymski T, Milani M, Singleton DC, et al. Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle. 2014;8:3838–3847.
   Web of Science ®Google Scholar
• Zhang M, He J, Liu Z, et al. Anti-beta(2)-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget. 2015;6:8567–8578.
   PubMed Web of Science ®Google Scholar
• Azab AK, Quang P, Azab F, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012;119:1468–1478.
   PubMed Web of Science ®Google Scholar
• Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113:4341–4351.
   PubMed Web of Science ®Google Scholar
• Garcia-Gomez A, De Las Rivas J, Ocio EM, et al. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. Oncotarget. 2014;5:8284–8305.
   PubMed Web of Science ®Google Scholar
• Markovina S, Callander NS, O’Connor SL, et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer. 2010;9:176.
   PubMed Web of Science ®Google Scholar
• Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23:1337–1341.
   PubMed Web of Science ®Google Scholar
• Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115:3416–3417.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679–686.
   PubMed Web of Science ®Google Scholar
• Ishii T, Seike T, Nakashima T, et al. Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012;2:e68.
   PubMed Web of Science ®Google Scholar